Maintains clinical progress with lead programs, Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder Thin Film Freezing platform technology employed in numerous partnership programs for vaccine and anti-viral applications Conference call and live webcast scheduled for Thursday, May 14,

Company to hold conference call and webcast at 5:00 PM EDT AUSTIN, Texas --(BUSINESS WIRE)--May 7, 2020-- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing

Data presented on repurposing the existing, broad-spectrum antiviral agent using Thin Film Freezing and other techniques to enhance its effect for COVID-19 therapy AUSTIN, Texas --(BUSINESS WIRE)--Apr. 30, 2020-- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company